Form 8-K - Current report:
SEC Accession No. 0001104659-25-043522
Filing Date
2025-05-01
Accepted
2025-05-01 16:15:32
Documents
13
Period of Report
2025-05-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513768d1_8k.htm   iXBRL 8-K 28447
  Complete submission text file 0001104659-25-043522.txt   203291

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA adap-20250501.xsd EX-101.SCH 3023
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE adap-20250501_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adap-20250501_pre.xml EX-101.PRE 22364
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2513768d1_8k_htm.xml XML 3748
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 25903313
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)